Description
Products
5 productsFYB203. Eylea biosimilar. nAMD, DME, CNV, PDR, RVO. Partner brands: Ahzantive (Teva, Europe; Valorum Biologics, US and Canada), Baiama (Horus Pharma, Europe; NTC, Italy), Fovlya (MS Pharma, MENA). US launch planned Q4 2026.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
FYB208. Dupixent biosimilar candidate (IL-4/IL-13). Atopic dermatitis, severe asthma, CRSwNP, COPD. Technical development (technical proof of similarity, Nov 2025); phase not stated.
Under development
Finished product (FDF)
Verified on 2026-10-21
FYB206. Keytruda biosimilar candidate (PD-1 inhibitor). Clinical stage: PK equivalence study completed; FDA-agreed programme without Phase III. Partners: Zydus (US/Canada), MS Pharma (MENA), Lotus (APAC).
Under development
Finished product (FDF)
Verified on 2026-10-21
FYB201. Lucentis biosimilar. Severe retinal diseases (wet AMD, DME, CNV, PDR, RVO). Partner brands: Ranivisio (Teva, EU and Canada; Biomm, Brazil), Ongavia (Teva, UK), Cimerli (Sandoz, US, interchangeable), Nufymco (Zydus, US), Epruvy (Sandoz, Germany), Ranopto (Teva, Canada), Ravegza and Uptera (MS Pharma, MENA).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
FYB202. Stelara biosimilar (ustekinumab-aauz in the US). Crohn's disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis. Partner brands: Otulfi (Fresenius Kabi), Fymskina (Teva/ratiopharm, Germany), Sitovab (MS Pharma, MENA).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21